Fierce Pharma

APRIL 9, 2024

Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred layoffs in its development organizational uni | Even as Novartis rolls ahead with a global restructuring campaign targeting thousands of job cuts, the Swiss drug giant has blueprinted several hundred (..)

120

120

PharmaShots

APRIL 17, 2023

2 P-I trials for PIPE-307 in healthy volunteers have been completed Ref: Businesswire | Image: Janssen Related News:- Janssen Reports P-I Study (CHRYSALIS) Results of Rybrevant (amivantamab-vmjw) for Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

40

40

Outsourcing Pharma

APRIL 29, 2024

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

105

105

Outsourcing Pharma

MARCH 24, 2022

The companyâs analysis of clinical research activity in the region shows the conflict will have long-lasting effects that reach beyond the countryâs borders.

59

59

Pharmaceutical Technology

APRIL 24, 2024

Pfizer and its Germany partner BioNTech have urged London’s High Court to invalidate competitor Moderna's patents over technology instrumental in the Covid-19 vaccines development as the latest phase of a global legal fight that started yesterday (23 April), reported Reuters.

Vaccines 130

Vaccines 130

PhRMA

APRIL 28, 2023

AMR occurs when microorganisms such as bacteria, viruses, fungi and parasites develop the ability to survive against the drugs designed to kill them. million globally on an annual basis – higher than HIV/AIDS and malaria. deaths each year and 1.27

211

211

Outsourcing Pharma

MAY 7, 2024

PCI Pharma Services, a global leader in contract development and manufacturing, has embarked on the installation of crucial equipment for its latest sterile fill-finish facility at its Bedford, NH campus in Philadelphia.

73

73

Pharmacy Times

FEBRUARY 21, 2024

National governments and global non-governmental organizations are trying to expand access to essential medicines and treatments in developing countries.

122

122

European Pharmaceutical Review

MARCH 5, 2024

BeiGene has appointed Pilar de la Rocha as its new Head of Europe, Global Clinical Operations. The biotech’s new appointment underlines its commitment to advancing clinical development initiatives in the European region. Pilar de la Rocha’s career journey to date Pilar de la Rocha as Head of Europe, Global Clinical Operations, Beigene.

Medical Schools 96

Medical Schools 96

STAT

MAY 6, 2024

has implications for the global pace and direction of innovation. The goals of these assessments are to ensure that society does not overpay for new medications, but also does not inadvertently discourage the development of worthwhile medicines and other health technologies. The changing landscape of drug pricing policy in the U.S.

Insurance 100

Insurance 100

STAT

MAY 8, 2024

The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally.

142

142

PhRMA

APRIL 12, 2023

The Global Access to New Medicines Report includes comprehensive comparisons across countries in the G20, Organization for Economic Co-operation and Development (OECD) and several geographic regions.

195

195

PharmaShots

APRIL 20, 2023

and in several global markets, including Japan and the European Union. Owens is the Global Brand Development Leader, Insulins, Glucagon & Devices at Eli Lilly & Company. Related Post: Leonard Glass, Vice President, Global Medical Affairs at Eli Lilly & Co. Japan and Saudi Arabia.

FDA 40

FDA Insurance Labelling 40

European Pharmaceutical Review

MAY 1, 2024

A new state-of-the-art research and laboratory building is being built on AbbVie’s main campus at its Rhineland-Palatinate site, the company ’s second largest research and development ( R&D ) location globally. The new R&D building in Germany is expected to completed in 2027.

95

95

STAT

APRIL 4, 2024

researchers discovered new antibiotics that turned once-fatal infections into minor ailments, and developed antiretroviral cocktails that transformed HIV from a death sentence into a manageable, chronic disease. The development of new biofuels could transform global politics as countries grow less reliant on oil-rich nations.

Vaccines 123

Vaccines 123

European Pharmaceutical Review

APRIL 16, 2024

A new global licensing agreement is set to advance development of an oncology biosimilar candidate. and Spain-based biopharmaceutical company mAbxience, have entered into a strategic deal for a drug candidate that is in development for treating multiple indications in the oncology space.

86

86

Fierce Pharma

SEPTEMBER 26, 2023

On a €1 billion quest to build a global mRNA network, Merck KGaA’s MilliporeSigma has rounded out its service offerings to include all key stages of mRNA development, manufacturing and commercializ | On a €1 billion quest to build a global mRNA network, Merck KGaA’s MilliporeSigma has rounded out its service offerings to include all key stages of mRNA (..)

117

117

STAT

MAY 7, 2024

Drug development is essentially a long, expensive bet: 90% of drugs fail during clinical trials, goes one of the life science industry’s most oft-quoted statistics. But they cautioned that the pace of future successes will depend on whether the industry can streamline and rethink drug development.

Vaccines 73

Vaccines 73

European Pharmaceutical Review

MARCH 27, 2024

Data from SwedenBIO’s 2023 Pipeline report shows that drug development companies with Swedish headquarters (excl. AstraZeneca), have a combined pipeline of the size of a global Pharma giant, but with 1/20 of the personnel”, according to Neiman. We also see that Swedish companies are very connected internationally.

90

90

Outsourcing Pharma

APRIL 29, 2024

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

52

52

PharmaShots

JUNE 27, 2023

Image Source: Canva About the Author: Dr. Mourad Farouk Rezk is the Head of Global Medical and Development Biogen Biosimilars. Related Post: Monica Mann, VP, of Medical Affairs for Global MS and Pipeline at Biogen Shares Insights on New Data on MS Therapies and Digital Health Research

Immunization 40

Immunization FDA 40

Outsourcing Pharma

OCTOBER 18, 2023

Emma Harvey is global head of medical affairs at F2G Ltd, a UK and Austria based biotech where she is responsible for the global medical and commercial strategies for a novel antifungal drug for serious systemic infections, in clinical development.

98

98

STAT

MARCH 21, 2024

After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once-fledgling company into the $100 billion global drugmaker it is today. George Yancopoulos is in touch with his teenage self.

127

127

STAT

NOVEMBER 1, 2023

The co-developers of the drug, the nonprofit Global Antibiotic Research & Development Partnership, or GARDP, and Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., released topline results of the clinical trial on Wednesday.

144

144

STAT

MAY 7, 2024

At a panel at the Milken Institute 2024 Global Conference Monday, Bastani and other health care leaders addressed the rapidly growing applications of AI in science and health care. Collectively, they acknowledged that developers and health systems have to think critically about AI’s limits to avoid harm to patients.

92

92

European Pharmaceutical Review

FEBRUARY 14, 2024

A report by Allied Market Research predicts that the global pharmaceutical suspension market will reach $83.8 The research specified that the parenteral administration sector accounted for more than half of the global pharmaceutical suspension market in 2022. billion by 2032. Having valued $55.5 percent between 2023 and 2032.

78

78

PharmExec

SEPTEMBER 20, 2023

The current vaccine pipeline brings promise of significant global health advancements—yet development gaps remain, and the future delivery challenges must be considered.

Vaccines 108

Vaccines 108

Pharmaceutical Technology

APRIL 23, 2024

Ipsen has entered an exclusive global collaboration with Skyhawk Therapeutics for the discovery and development of new small molecules that can modulate RNA for treating rare neurological disorders.

52

52

Fierce Pharma

OCTOBER 18, 2023

EVP, Global Head of Research and Development at Jazz Pharmaceuticals | Learn more about how Jazz Pharmaceuticals harnesses the therapeutic potential of cannabinoids to drive patient-centric innovation By Robert Iannone, M.D.,

113

113

Outsourcing Pharma

NOVEMBER 21, 2023

OSP was delighted to talk to Vetterâs Carsten Press, a senior leader of the global sales organization, and business development among many operational functions.

93

93

STAT

OCTOBER 2, 2023

Just two years after the World Health Organization’s historic recommendation of the first malaria vaccine, the global health agency on Monday recommended a second , seeking to broaden access to a tool it hopes can save lives.

Vaccines 132

Vaccines 132

ISPE

SEPTEMBER 5, 2023

Opening Ceremony At the opening ceremony, Tom Hartman, President and CEO of ISPE presented on global innovation and development trends of biopharmaceutical engineering. GAMP ® Sion Wyn, Director at Conformity Ltd.

FDA 98

FDA 98

STAT

APRIL 10, 2024

Novartis plans to cut up to 680 jobs in its product development organization , Reuters notes. The job eliminations are separate from a restructuring program that could lead to 8,000 of its 78,000 global workforce being cut. Around 440 jobs will go in Switzerland and up to 240 in the U.S. over the next two to three years.

99

99

Outsourcing Pharma

SEPTEMBER 14, 2023

Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firmâs small molecule cancer treatment.

105

105

European Pharmaceutical Review

JANUARY 25, 2024

Eli Lilly and Company’s Executive Vice President of Global Quality, Johna Norton, is ending her lengthy tenure with the company this summer and retiring after 34 years of service. “During her tenure as leader of Global Quality, Johna has overseen significant expansion, modernisation of systems and improvements in our processes and team.”

Pharmaceutical Companies 95

Pharmaceutical Companies Pharmaceutical Companies 95

European Pharmaceutical Review

NOVEMBER 14, 2023

This ‘manifesto for growth’, developed by the Manufacturing Five (M5), a coalition of the UK’s leading advanced trade associations, proposed the reforms necessary for the UK to close the gap with global competitors and growth of innovative manufacturing in the country. Article: Are we globally prepared for the next pandemic?

99

99

European Pharmaceutical Review

JANUARY 24, 2024

The first in our inaugural Pharma Horizons report series is dedicated to exploring the latest advances in artificial intelligence (AI) and machine learning (ML) for drug development, pharmaceutical manufacturing and quality control. Additionally the pharmaceutical AI market is projected to reach $11.8 Download for free today!

129

129